A systematic review and meta-analysis of 25 randomized controlled trials found that resveratrol supplementation was associated with a modest reduction in C-reactive protein (CRP) in people with metabolic disorders. Effects on other inflammatory and oxidative stress biomarkers were inconclusive or null.
Source: Pooled analysis of studies, patients with metabolic disorders. It combines earlier studies, so its strength depends on the studies it pooled.
What was found
Resveratrol supplementation was associated with a modest reduction in C-reactive protein (CRP) in people with metabolic disorders, according to a systematic review and meta-analysis. Trial sequential analysis supported this anti-inflammatory effect for CRP.
The review found non-significant changes for other inflammatory markers, including interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-α). No significant overall effects were observed for oxidative stress markers such as catalase (CAT), malondialdehyde (MDA), or superoxide dismutase (SOD).
A non-significant trend for total antioxidant capacity (TAC) became statistically significant only after the exclusion of one trial. No significant linear or non-linear associations were identified between daily resveratrol dosage and inflammatory outcomes.
How it was done
Researchers conducted a systematic review and dose-response meta-analysis of randomized controlled trials (RCTs). They searched for RCTs that examined the effect of resveratrol on inflammatory biomarkers (CRP, TNF-α, IL-6) and oxidative stress biomarkers (MDA, SOD, CAT, TAC) in people with metabolic disorders.
The meta-analysis included 25 RCTs for CRP. Random effects models were used to combine data, and trial sequential analysis was performed to assess the robustness of the evidence.
What it does not show
The review found high heterogeneity for some inflammatory markers. The absence of a clear dose-response relationship and the surrogate status of CRP limit the clinical interpretability of these findings. Evidence for most biomarkers remained inconclusive.
Who was talking about it
- Inflammopharmacology on journal (2026-10-17): Inflammopharmacology reported that resveratrol supplementation was associated with a modest reduction in CRP, but effects on other biomarkers were null or inconclusive. See the post
The source
This is news, reported from the source above. It is not medical advice and not a recommendation. Talk to your doctor or pharmacist before you change any medicine or supplement.